GenScript Biotech Corporation along with its subsidiary, GenScript ProBio, and Ligand Pharmaceuticals Incorporated announced that they have entered into a strategic licensing agreement for Ligand's OmniAb® Platform, a multi-species antibody discovery platform, to generate highly diversified, fully human antibodies that are optimized in vivo for immunogenicity, manufacturability and efficacy. Under the terms of the agreement, GenScript is now able to offer its global customers access to the OmniAb rodent platforms for high-quality, rapid, fully human antibody discovery services.
"We are excited to enter into this new relationship with Ligand, which has one of the best antibody discovery platforms in the world," said Brian Min, Ph.D., CEO of GenScript ProBio. "GenScript is committed to helping our customers expand their pipelines of innovative antibody products and advance their biological drugs to market more quickly. We believe that our deep experience in antibody discovery services combined with Ligand's premier transgenic antibody discovery platform will accomplish those goals and ultimately bring better treatment options to patients."
GenScript ProBio, already a qualified OmniAb contract research organization (CRO) for antibody discovery services, is now the second contract development and manufacturing organization (CDMO) in China to secure a global license to the transgenic rodent technology of the OmniAb platform. With more than 16 years of experience in custom antibody services for various targets, GenScript ProBio provides a range of immunization methods. By combining a single B cell screening platform with transgenic rodent platforms, GenScript ProBio is capable of generating fully human therapeutic antibodies in one month, thereby significantly accelerating research and development.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from Pharmaceutical Outsourcing – all delivered right to your inbox!
Sign up now!